Q1 FY27 standalone results: revenue down 12% YoY

Revenue DeclineResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.2%Reaction day

₹28.58

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-7.1% vs market

Pharmaceuticals peers, median of 164sector+0.1%-7.3% vs sector

On the reaction day the stock moved 7.1 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.2-0.2-7.1+0.1-7.3

Next day

-4.8+0.2-5.0-0.4-4.4

+1.2+0.4+0.8+0.1+1.1

+3.2+0.4+2.8-0.5+3.7

-2.0+0.6-2.6-0.9-1.1

-1.4+0.9-2.4-0.5-1.0

-5.5+0.9-6.4-1.0-4.6

15d

+3.9+0.9+3.0-0.8+4.7

-4.7+2.3-7.0+1.1-5.8

+20.6-1.1+21.8-3.1+23.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kimia Biosciences posted Q1 FY27 standalone results. Revenue from operations fell 12% YoY to Rs 20.7 crore versus Rs 23.6 crore in Q1 FY26. Total income was Rs 20.8 crore and expenses Rs 16.6 crore. Basic EPS was Rs 0.08 for the quarter versus Rs 0.13 YoY. FY26 full year revenue was Rs 114.9 crore with EPS of Rs 1.64. The auditor issued an unqualified limited review report.

Likely market impact

Mildly negative: revenue decline YoY and lower per-share earnings signal a weak quarter for this small pharma player.